Anfarm Hellas S.A. - Main Component
| Active Substance | Strength | Form |
|---|---|---|
| Amikacin | 1g/4ml | Inj.Sol |
| Apixaban | 2.5mg/tab & 5mg/tab | F.C.Tabs |
| Brivaracetam | 10mg/ml | Sol.Inf |
| Brivaracetam | 10mg/ml | Oral Solution |
| Ceftaroline Fosamil | 600mg/vial | Pd.C.So.In |
| Clindamycin | 150mg/ml | Inf.Sol |
| Dalbavancin | 500mg/vial | Pd.C.So.In |
| Ertapenem | 1g/Vial | Pd.C.So.In |
| Isavuconazole | 200mg/vial | Pd.C.So.In |
| Lacosamide | 10mg/ml | Sol.Inf |
| Lacosamide | 10mg/ml | Oral Solution |
| Vancomycin | 1g/vial | Pd.Sol.Inf |
| Vildagliptin/Metformin | (50+850)mg/tab & (50+1000)mg/tab | Tabs |
| Active Substance | Strength | Form |
|---|---|---|
| Amikacin | 1g/4ml | Inj.Sol |
| Apixaban | 2.5mg/tab & 5mg/tab | F.C.Tabs |
| Brivaracetam | 10mg/ml | Sol.Inf |
| Brivaracetam | 10mg/ml | Oral Solution |
| Ceftaroline Fosamil | 600mg/vial | Pd.C.So.In |
| Clindamycin | 150mg/ml | Inf.Sol |
| Dalbavancin | 500mg/vial | Pd.C.So.In |
| Ertapenem | 1g/Vial | Pd.C.So.In |
| Isavuconazole | 200mg/vial | Pd.C.So.In |
| Lacosamide | 10mg/ml | Sol.Inf |
| Lacosamide | 10mg/ml | Oral Solution |
| Vancomycin | 1g/vial | Pd.Sol.Inf |
| Vildagliptin/Metformin | (50+850)mg/tab & (50+1000)mg/tab | Tabs |
| Active Substance | Strength | Form | Dossier Availability |
|---|---|---|---|
| Amikacin | 1g/4ml | Inj.Sol | Q3 2021 |
| Apixaban | 2.5mg/tab & 5mg/tab | F.C.Tabs | on going |
| Brivaracetam | 10mg/ml | Sol.Inf | Q3 2022 |
| Brivaracetam | 10mg/ml | Oral Solution | Q4 2022 |
| Ceftaroline Fosamil | 600mg/vial | Pd.C.So.In | on going |
| Clindamycin | 150mg/ml | Inf.Sol | Q3 2022 |
| Dalbavancin | 500mg/vial | Pd.C.So.In | on going |
| Ertapenem | 1g/Vial | Pd.C.So.In | on going |
| Isavuconazole | 200mg/vial | Pd.C.So.In | on going |
| Lacosamide | 10mg/ml | Sol.Inf | Q1 2021 |
| Lacosamide | 10mg/ml | Oral Solution | Q2 2022 |
| Vancomycin | 1g/vial | Pd.Sol.Inf | Q3 2021 |
| Vildagliptin/Metformin | (50+850)mg/tab & (50+1000)mg/tab | Tabs | Q3 2021 |
